Ocata Therapuetics was a biotechnology company focused on the development of regenerative therapeutics using stem cells in ophthalmology and other disease areas. The company was acquired by Asrellas Pharma in 2015.
In Phase 1/2 clinical trials MA09-hRPE cells were administered in suspension form beginning in April 2011 and completed in 2017 in eye centers in the United StatesUnited States, United Kingdom and South Korea (Clinicaltrial.gov identifiers: UK-SMD: NCT01469832; US-SMD: NCT01345006; US-AMD: NCT01344993).
Ocata Therapeutics, originally named Advanced Cell Technology, pioneered the first clinical investigation using human embryonic stem cellstem cell derived Retinal Pigment Epithelium (RPE) to treat retinal diseases including Stargardts Macular Degeneration (SMD) and Geographic Atrophy (GA), secondary to Age-related Macular Degeneration (AMD). The cell line generated by the company is named MA09-hRPE.